No products in the cart.
Pre-made Opicinumab benchmark antibody ( Whole mAb, anti-LINGO1 therapeutic antibody, Anti-LERN1/LRRN6A/MRT64/UNQ201 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-407
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Opicinumab biosimilar, Whole mAb, Anti-LINGO1 Antibody: Anti-LERN1/LRRN6A/MRT64/UNQ201 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Opicinumab (BIIB033) is a fully human monoclonal antibody designed for the treatment of multiple sclerosis, acute optic neuritis (AON), and other associated demyelinating diseases. A biologic drug, it is designed to function as a LINGO-1 protein antagonist, known as ¡°Anti-Lingo-1¡±.
| Products Name (INN Index) | Pre-Made Opicinumab biosimilar, Whole mAb, Anti-LINGO1 Antibody: Anti-LERN1/LRRN6A/MRT64/UNQ201 therapeutic antibody |
|---|---|
| INN Name | Opicinumab |
| Target | LINGO1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 4oqt:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Biogen Idec,Dyax,Biogen |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Multiple sclerosis,Optic neuritis |
| Development Tech | Dyax Human Phage Display |
| Previous Name | NA |
| Gm Offical Target Name | LINGO1 |
| Package |
Previous slide
Next slide
